Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) — Working Capital to Net Assets Ratio
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) has a Working Capital to Net Assets ratio of 31.7% as of March 2026. Working capital of CN¥791.96 Million (current assets of CN¥1.70 Billion minus current liabilities of CN¥906.46 Million) is measured against net assets of CN¥2.50 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Hangzhou Bio-Sincerity Pharma-Tech Co.Lt defensive interval ratio to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. Working Capital to Net Assets (2019–2025)
This chart shows how Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s Working Capital to Net Assets ratio has evolved across 7 annual periods from 2019 to 2025. As of March 2026, the ratio stands at 31.7%, reflecting working capital of CN¥791.96 Million against net assets of CN¥2.50 Billion CNY. For the complete balance sheet picture, see Hangzhou Bio-Sincerity Pharma-Tech Co.Lt (301096) total assets.
Annual Working Capital to Net Assets for Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (2019–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. from 2019 to 2025, covering 7 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check Hangzhou Bio-Sincerity Pharma-Tech Co.Lt liquid asset ratio to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 25.4% | CN¥632.17 Million | CN¥2.49 Billion | CN¥1.55 Billion | CN¥919.91 Million | ▼ -4.7 pp |
| 2024 | 30.1% | CN¥776.10 Million | CN¥2.58 Billion | CN¥1.55 Billion | CN¥769.38 Million | ▲ +1.7 pp |
| 2023 | 28.4% | CN¥761.59 Million | CN¥2.68 Billion | CN¥1.61 Billion | CN¥846.19 Million | ▼ -24.8 pp |
| 2022 | 53.1% | CN¥1.32 Billion | CN¥2.48 Billion | CN¥1.61 Billion | CN¥290.70 Million | ▼ -22.5 pp |
| 2021 | 75.6% | CN¥1.75 Billion | CN¥2.32 Billion | CN¥2.23 Billion | CN¥472.69 Million | ▲ +41.1 pp |
| 2020 | 34.5% | CN¥117.10 Million | CN¥339.54 Million | CN¥238.79 Million | CN¥121.69 Million | ▼ -22.3 pp |
| 2019 | 56.8% | CN¥158.36 Million | CN¥278.74 Million | CN¥232.66 Million | CN¥74.30 Million | — |